Screening study of new thiazolidinone derivatives for anticonvulsant activity

Authors

DOI:

https://doi.org/10.14739/2310-1210.2020.6.218463

Keywords:

antiepileptic drugs, epilepsy, thiazolidinone derivatives

Abstract

 

The search for new antiepileptic drugs that would have greater margins of safety and fewer adverse effects is relevant. Thiazolidinone are a promising class for the development of new anticonvulsants.

Aim. To conduct a screening study of new thiazolidinone derivatives for anticonvulsant activity on a seizure model induced by pentylenetetrazole and maximal electroshock; to analyze the structure – activity relationship; to reveal a lead-compound and investigate its dose-dependent manner.

Materials and methods. Basic screening seizure models of pentylenetetrazol and maximal electroshock test were used in mice. The test original 9 thiazolidinone derivatives (100 mg/kg) and the reference drugs of sodium valproate (300 mg/kg), carbamazepine (40 mg/kg) were administered intragastrically 30 minutes before subcutaneous administration of pentylenetetrazol (90 mg/kg) or induction with maximal electroshock by giving a current with strength of 50 mA and frequency of 50 Hz for 0.2 s. In order to study the dose-dependent manner, the lead-compound was administered intragastrically in doses ranging from 25 mg/kg to 150 mg/kg.

Results. A total of 9 compounds were studied, of which 3 did not affect experimental convulsions, 2 showed proconvulsive activity, and 4 had an anticonvulsant effect. The lead-compound 5-[(Z)-(4-nitrobenzylidene)]-2-(thiazol-2-ylimino)-4-thiazolidinone was determined under laboratory code Les-6222, which exhibited the highest anticonvulsant properties. The “structure–anticonvulsant activity” relationship in a series of thiazolidinone derivatives was analyzed. The dose-dependent manner of 5-[(Z)-(4-nitrobenzylidene)]-2-(thiazol-2-ylimino)-4-thiazolidinone anticonvulsant effect was studied using 2 seizure models, and the most effective dose of 100 mg / kg was identified.

Conclusions. 5-[(Z)-(4-nitrobenzylidene)]-2-(thiazol-2-ylamino)-4-thiazolidinone is a promising compound for in-depth studies on anticonvulsant and related pharmacological activities in order to develop new original anticonvulsants.

References

Espinosa-Jovel, C., Toledano, R., Aledo-Serrano, Á., García-Morales, I., & Gil-Nagel, A. (2018). Epidemiological profile of epilepsy in low income populations. Seizure, 56, 67-72. https://doi.org/10.1016/j.seizure.2018.02.002

Chen, Z., Brodie, M. J., Liew, D., & Kwan, P. (2018). Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study. JAMA Neurology, 75(3), 279-286. https://doi.org/10.1001/jamaneurol.2017.3949

Bigelow, M. D., & Kouzani, A. Z. (2019). Neural stimulation systems for the control of refractory epilepsy: a review. Journal of NeuroEngineering and Rehabilitation, 16(1), Article 126. https://doi.org/10.1186/s12984-019-0605-x

Nikalje, A. P., Ansari, A., Bari, S., & Ugale, V. (2015). Synthesis, Biological Activity, and Docking Study of Novel Isatin Coupled Thiazolidin-4-one Derivatives as Anticonvulsants. Archiv Der Pharmazie, 348(6), 433-445. https://doi.org/10.1002/ardp.201500020

Jangam, S. S., Wankhede, S. B., & Chitlange, S. S. (2018). Molecular docking, synthesis and anticonvulsant activity of some novel 3-(2-substituted)-4-oxothiazolidine-3-yl)-2-phenylquinazoline-4(3H)-ones. Research on Chemical Intermediates, 45(2), 471-486. https://doi.org/10.1007/s11164-018-3612-9

Archana, & Saini, S. (2018). Synthesis and evaluation of some newerthiazolidinonyl substituted quinazolinones as potent anticonvulsant agents. International Journal of ChemTech Research, 11(11), 09-16. https://doi.org/10.20902/ijctr.2018.111102

Faizia, M., Jahania, R., Ebadib, S. A., Tabatabaic, S. A., Rezaeec, E., Lotfalieic, M., Aminid, M., & Almasiradb, A. (2017). Novel 4-thiazolidinone derivatives as agonists of benzodiazepine receptors: design, synthesis and pharmacological evaluation. EXCLI Journal, 16, 52-62. http://dx.doi.org/10.17179/excli2016-692

Kaur Manjal, S., Kaur, R., Bhatia, R., Kumar, K., Singh, V., Shankar, R., Kaur, R., & Rawal, R. K. (2017). Synthetic and medicinal perspective of thiazolidinones: A review. Bioorganic Chemistry, 75, 406-423. https://doi.org/10.1016/j.bioorg.2017.10.014

Pandey, A. K. (2019). Anticonvulsant activity of novel Schiff bases of thiadiazole derivatives. Bangladesh Journal of Pharmacology, 14(3), 127-128. https://doi.org/10.3329/bjp.v14i3.41543

Myronenko, S. I., Pinyazhko, О. R., & Lesyk, R. B. (2015). Skryninh spoluk z protysudomnoiu aktyvnistiu sered pokhidnykh 4-tiazolidynonu [Screening of compounds with anticonvulsant activity among 4-thiazolidinone derivatives]. Farmakolohiia ta likarska toksykolohiia, (4-5), 33-38. [in Ukrainian].

Mishchenko, M. V., Shtrygol, S. Yu., Lesyk, R. B., & Kaminskyi, D. V. (2019). Tiazolzamishcheni pokhidni 2,4-tiazolidyndionu, shcho vyiavliaiut antykonvulsantnu diiu [Thiazole-substituted 2,4-thiazolidinedione derivatives exhibiting anticonvulsant activity] (Ukraine. Patent No. 137726). Ukraina. Derzhavna sluzhba intelektualnoi vlasnosti Ukrainy. https://base.uipv.org/searchINV/search.php?action=viewdetails&IdClaim=262912 [in Ukrainian].

Myronenko, S. I., Kaminskyy, D. V., Nektegayev, I. O., Pinyazko, O. R., & Lesyk, R. B. (2012). Poshuk novykh antykonvulsantnykh ahentiv v riadu 4-tiazolidynoniv ta sporidnenykh heterotsyklichnykh system [Search of new anticonvulsant agents among 4-thiazolidinones and related heterocyclic systems]. Klinichna farmatsiia, farmakoterapiia ta medychna standartyzatsiia, (1-2), 124-131. [in Ukrainian].

Hock, F. J. (Ed.). (2016). Drug Discovery and Evaluation: Pharmacological Assays. Springer, Cham. https://doi.org/10.1007/978-3-319-05392-9

Mironov, A. N., Bunyatyan, N. D., Vasil'ev, A. N., Verstakova, O. L., Zhuravleva, M. V., Lepakhin, V. K., Korobov, N. V., Merkulov, V. A., Orekhov, S. N., Sakaeva, I. V., Uteshev, D. B., & Yavorskii, A. N. (Eds.). (2012). Rukovodstvo po provedeniyu doklinicheskikh issledovanii lekarstvennykh sredstv. Chast' pervaya [Guidelines for conducting preclinical studies of drugs. Part one]. ZAO «Grif i K». [in Russian].

How to Cite

1.
Mishchenko MV, Shtrygol SY, Lesyk RB, Lozynskyi AV, Holota SM. Screening study of new thiazolidinone derivatives for anticonvulsant activity. Zaporozhye Medical Journal [Internet]. 2020Dec.9 [cited 2024Nov.13];22(6). Available from: http://zmj.zsmu.edu.ua/article/view/218463

Issue

Section

Original research